US EditionEmerin Is an Effector of Oncogenic KRAS-Driven Nuclear Dynamics in Pancreatic Cancer.
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Emerin Is an Effector of Oncogenic KRAS-Driven Nuclear Dynamics in Pancreatic Cancer.
Using a model of PDAC, the major histological subtypes of pancreatic cancer, researchers found oncogenic mutant KRAS reduces nuclear size. Transcriptomic and protein expression analysis of mutant KRAS-expressing PDAC cells revealed differential levels of several nuclear envelope-associated genes. [JCI Insight] AbstractGraphical Abstract
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium